Remacemide hydrochloride: A double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke

Stroke

Volumn 30, Issue 9, 1999, Pages 1796-1801

  Dyker, A G ^a   Lees, K R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Glutamates; N methyl D aspartate; Neuroprotection; Remacemide

Indexed keywords

REMACEMIDE;

ADULT; AGED; ARTICLE; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HUMAN; HYPERREFLEXIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; NEUROPROTECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0032875690     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.9.1796     Document Type: Article

References (16)

1. Black MA, Tremblay R, Mealing GAR, Durkin JP, Whitfield JF, Morley P. The desglycinyl metabolite of remacemide hydrochloride is neuroprotective in cultured rat cortical neurons. J Neurochem. 1996;66:989-995.
2. Palmer GC, Clark B, Hutchison JB. Antiepileptic and neuroprotective potential of remacemide hydrochloride. Drugs Future. 1993;18: 1021-1042.
3. Bannan PE, Graham Dl, Lees KR, McCulloch J. Neuroprotective effect of remacemide hydrochloride in focal cerebral ischaemia in the cat. Brain Res. 1994;664:271-275.
4. Palmer GC, Jamieson V, Jones T. Remacemide. In: Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia, Pa: Lippincott-Raven Press; 1997:1659-1664.
5. Cole R, Hachinski VC, Shurvell BL, Norris JW, Wolfson C. The Canadian Neurological Scale: a preliminary study in acute stroke. Stroke. 1986;17:731-737.
6. Flynn JW, O'Brien JE. High-performance liquid-chromatographic method for the simultaneous measurement of remacemide (a novel anti-convulsant and cerebroprotectant) and an active metabolite in human plasma. J Chromatogr B Biomed Appl. 1992;583:91-97.
7. Mahoney Fl, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61-65.
8. Wahlgren NG, MaCMahon DG, De Keyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis. 1994;4:204-210.
9. Muir KW, Grosset OG, Lees KR. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Clin Neuropharmacol. 1997;20:311-321.
10. Fisher M, for the CNS 1102-003 Investigators. Cerestat™ (CNS 1102), a non-competitive NMDA antagonist, in ischaemic stroke patients: dose-escalating safety study. Cerebrovasc Dis. 1994;4:245. Abstract.
11. Heiss WD. Flow thresholds of functional and morphological damage of brain tissue. Stroke. 1983;14:331. Abstract.
12. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischaemia: the ischemic penumbra. Stroke. 1981;12:723-725.
13. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581-1587.
14. The European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274:1017-1025.
15. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M. Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet. 1995;345:57. Letter.
16. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.